{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Podcast","title":"Triple threat for BPDCN and Human Milk Oligosaccharides after HSCT","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/7a1d0e49\"></iframe>","width":"100%","height":180,"duration":1792,"description":"In this week's episode, Blood editor Dr. Laurie Sehn interviews Dr. Andrew Lane from the Dana-Farber Cancer Institute and Dr. Pooja Khandelwal from the Cincinnati Children's Hospital Medical Center on their latest articles published in Blood on new drug combinations for BPDCN and reduced intestinal dysbiosis after HSCT. Dr. Lane discusses \"Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm\" and after, Dr. Khandelwal discusses \"Human milk oligosaccharide (2′-FL) modifies the gut microbiome in children after bone marrow transplant\".","thumbnail_url":"https://img.transistorcdn.com/v7MGyoJEM-ebFBYi5VpSwDRF3QY3zbinfCyyOAH1TGk/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kY2Q4/YzJhZmMwODBjOWRi/YTNhN2Y1NWJkMzMw/NTBjZi5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}